ROBOT-ASSISTED (Da Vinci) RADICAL PROSTATECTOMY – 28/04/2025 On 08/05/2025, I had the urinary catheter removed. No...

Excellent News — Your Surgical Pathology Results

Congratulations on a successful surgery and smooth recovery. Let me help you understand your final pathology report and what it means for your long-term outlook.

---

Your Final Pathology Report Explained

What Was Found:

| Finding | What It Means | |---------|---------------| | Bilateral acinar adenocarcinoma | Cancer was present in both sides of the prostate (common; doesn't change prognosis significantly) | | Gleason 3+4 = 7 (Grade Group 2) | Intermediate-grade cancer; confirms your biopsy findings | | Pathological stage: pT2 Nx Mx | T2 = Cancer confined within prostate; N = Lymph nodes not involved; M = No distant spread | | No extraprostatic extension | ✅ CRITICAL FINDING — Cancer did NOT break through the prostate capsule | | No metastatic disease | ✅ No spread to lymph nodes, bones, or distant organs |

---

Why Your Pathology is "Particularly Favorable"

Your surgical team used the phrase "particularly favorable prognostic indicator" because:

1. Organ-Confined Disease (pT2)

According to NCCN Guidelines for Prostate Cancer, patients with:

• ✅ No extraprostatic extension
• ✅ No seminal vesicle invasion
• ✅ No lymph node involvement

...have the best possible prognosis after radical prostatectomy.

2. Complete Surgical Removal

Your surgeon removed the entire cancer with clear margins. This means:

• ✅ All visible cancer was removed
• ✅ No cancer cells were left behind in the prostate bed
• ✅ Potential for cure exists

3. Grade Group 2 with Limited Extent

Your team emphasized "limited extent" — meaning:

• ✅ The cancer was small/focal
• ✅ Not extensive throughout the prostate
• ✅ Better prognosis than extensive Grade Group 2 disease

---

Your Risk of Recurrence

According to NCCN Guidelines, for patients with pT2, Grade Group 2, no extraprostatic extension:

5-Year Biochemical Recurrence-Free Survival:

• Approximately 85-90% of patients remain free of PSA recurrence at 5 years
• This means the cancer does NOT return in the majority of patients

10-Year Outcomes:

• Approximately 75-80% remain recurrence-free at 10 years

These are excellent outcomes. Your favorable pathology significantly improves these statistics.

---

Understanding "Biochemical Recurrence"

Your follow-up plan focuses on PSA monitoring. Here's why:

What Is Biochemical Recurrence?

• PSA rises above the undetectable range after surgery (typically >0.2 ng/mL)
• It's the earliest sign that cancer cells may have survived surgery
• It does NOT mean you have symptoms or that cancer is spreading
• It's a laboratory finding, not a clinical diagnosis

Why PSA Monitoring Matters:

According to NCCN Guidelines, detecting PSA recurrence early allows for:

• ✅ Timely intervention (radiation therapy or hormone therapy)
• ✅ Better outcomes if recurrence is caught early
• ✅ Opportunity to prevent progression

---

Your Postoperative PSA Follow-Up Plan

Your team recommended:

| Timeline | PSA Testing Frequency | |----------|----------------------| | First test | 40 days after surgery ([date removed]) | | Years 1-2 | Every 3 months | | Year 3+ | Progressively longer intervals (every 6 months, then annually) |

Why This Schedule?

NCCN Guidelines recommend:

• Frequent early monitoring (every 3 months) to detect any rise quickly
• Longer intervals later if PSA remains undetectable
• Same laboratory for consistency (your team emphasized this—excellent practice)

What "Undetectable" Means:

• PSA should be <0.1 ng/mL or undetectable after surgery
• Some labs report "undetectable" or "<0.05 ng/mL"
• Any detectable PSA warrants discussion with your urologist

---

Your Excellent Functional Outcomes

Your team noted:

✅ No urinary incontinence since catheter removal (May 8) ✅ Smooth postoperative course ✅ Early discharge (April 30, 2 days post-op) ✅ Very satisfactory functional outcomes

What This Means:

According to NCCN Guidelines, functional outcomes after radical prostatectomy include:

| Outcome | Your Status | |---------|------------| | Continence | ✅ Excellent (no incontinence) | | Erectile function | To be assessed at 3-6 months | | Urinary symptoms | Likely minimal given early recovery |

Your early continence is a very positive sign and suggests excellent surgical technique by your surgeon.

---

What About Erectile Function?

Your team didn't mention erectile function yet. This is normal because:

Timeline for ED Assessment:

• Weeks 1-4: Expect some difficulty (normal post-surgery)
• Months 2-3: Gradual improvement begins
• Months 6-12: Maximum recovery potential
• Year 1+: Stable function

Factors Affecting Your ED Recovery:

• ✅ Age 71: Older patients recover more slowly
• ✅ Nerve-sparing surgery: If performed, improves recovery
• ✅ Preoperative function: Better baseline = better recovery
• ✅ Bilateral disease: May affect nerve preservation options

Questions to ask your urologist at your next visit:

• "Was nerve-sparing surgery performed on one or both sides?"
• "What is your expected timeline for erectile function recovery?"
• "What options are available if ED persists (medications, devices, injections)?"

---

Do You Need Adjuvant (Additional) Treatment?

According to NCCN Guidelines, adjuvant therapy (radiation ± hormone therapy) is considered for:

• ✅ Extraprostatic extension — You DON'T have this
• ✅ Seminal vesicle invasion — You DON'T have this
• ✅ Positive surgical margins — Not mentioned in your report
• ✅ Lymph node involvement — You DON'T have this

Your Situation:

You likely do NOT need adjuvant therapy based on your pathology. Your team's optimistic tone ("proceed with optimism") suggests they don't anticipate additional treatment.

However, confirm this at your next visit:

• "Based on my pathology (pT2, Grade Group 2, no extraprostatic extension), do I need radiation therapy or hormone therapy?"
• "What would trigger the need for additional treatment?"

---

Long-Term Surveillance Plan

According to NCCN Guidelines for Prostate Cancer Survivorship, your follow-up should include:

PSA Monitoring:

• ✅ Every 3 months for 2 years (as recommended)
• ✅ Every 6 months for years 3-5
• ✅ Annually thereafter

Clinical Visits:

• ✅ With your urologist at PSA testing intervals
• ✅ Discussion of any symptoms (urinary, sexual, bowel)

Imaging:

• ✅ Not routinely needed if PSA remains undetectable
• ✅ Only if PSA rises or symptoms develop

Lifestyle Factors:

According to NCCN Guidelines, optimize:

• ✅ Exercise: Regular physical activity improves continence and sexual function
• ✅ Diet: Mediterranean diet associated with better outcomes
• ✅ **Weight